US Patent

US9855214 — Enalapril compositions

Formulation · Assigned to University of Kansas · Expires 2032-11-06 · 6y remaining

Vulnerability score 30/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects stable enalapril powder compositions for oral liquid formulation used in the treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction.

USPTO Abstract

Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.

Drugs covered by this patent

Patent Metadata

Patent number
US9855214
Jurisdiction
US
Classification
Formulation
Expires
2032-11-06
Drug substance claim
No
Drug product claim
Yes
Assignee
University of Kansas
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.